Puneet Souda

Can you elaborate how CAM improved throughout the quarter? Your confidence here, is this more semi driven or instrumentation

Your diversification beyond health care seems to be helping you. But could you take a minute and provide a view into the pharma and the biotech business

where are you seeing that? Is that more on the LC/MS instrumentation side cell analysis?

Any update on -- to the full utilization of Train C, which I think is anticipated in 2027. The question is really around the margin impact

just trying to get a sense of if there's an acceleration in the near term. And and, obviously, you're seeing a normal budget flush replacement cycle is working.

Can you just elaborate a bit on what you're seeing in their quarter in China in third quarter?

can you size how much of the China growth in the quarter was from the sort of the Lunar New Year timing perspective

Just trying to understand how should we think about the Infinity III replacement cycle? How is it doing in the environmental labs versus the pharma labs?

can you elaborate the margin contribution? You talked about pricing on one end, number of cost efforts and also reducing some of the management changes

could you elaborate on your manufacturing and final assembly positions just globally so we can understand sort of how much of the product is sort of China for China

given the launch timing, was there any pause that you saw in on the instrumentation? And what is the order book telling you?

There is a 20% pricing rebate for those manufacturing locally. This is beyond the VBP and the DRG headwinds

just wondering if you could provide any color on the order growth or book-to-bill in the quarter

Can you talk to us about the updated number there? And just given the inter-quarter changes with US-China trade

how broad is the exposure to gene therapies? And I totally recognize that, you know, innovation doesn't come without risk

the USPSTF members, as you saw, the committee has been purged and there's an expectation new members are going to come in. Just wanted to get your thoughts

can you elaborate a little bit about how do you see that conversion in the last quarter here and then '26?

can you elaborate a little bit on the incentive comp changes and the sales rep changes in the field?

Does this change your appetite for further M&A and capital deployment in the space?

What are some of the steps there that you're taking that could yield sort of an immediate or near-term result?

just on the academic and government side, I know the reagent exposure is there. So just trying to understand if the grants are fewer next year

the improvement that you're seeing in this quarter, is it more of the, you know, China tariffs impacted situation from the last quarter?

Can you talk a little bit about how much of that was installed in new contracts versus continuing licensing and service?

just indirect exposure that you have and just given the sort of funding challenge that might arise there

Wondering, if you can elaborate if there was any one-timers in the quarter. Any upside from Signals versus ChemDraw licenses?

I appreciate the meaningful step up that needs to happen in the fourth fiscal quarter here. In organic growth

China, it's the third quarter. We are in a positive territory, and the growth is accelerating

are you continuing to see the momentum on new clinical trial adds?

can you talk a little bit about what instruments are driving growth there? Lunaphore was obviously weak in academic setting

Are you expecting low single digit for the full year fiscal '26? And if you could talk a little bit about the cadence of that over the next 4 quarters

I'm wondering what you can provide there, just given a lot of -- I appreciate the uncertainty, but with China, NIH and with tariffs

Could you provide more context into that, Jim, in terms of the impact you're expecting on academic, I mean, it's a meaningful reduction versus what you had before

can you talk a little bit about the pull forward that you saw from Q3 to Q2 in cell and gene therapy GMP products?

How does that shape your opportunity base when looking at

are these new trial starts or existing trials that are scaling up or moving into later phases?

could you elaborate how sustainable is that momentum and speak to both the spatial versus the diagnostic side of the business

could you elaborate what you're hearing from your larger biopharma large cap customers versus the early emerging biotechs

Could you talk a bit about how much of the growth was driven by volume in the quarter

Are you seeing sort of a pull forward of that replacement cycle peak

was there any contribution from extra selling days in Q1 that you're contemplating

on 4Q, just wondering if you're expecting a budget flush in the fourth quarter. If there are any pull forwards in the third quarter

With the subscription-based model, how should we think about the incremental upside here versus the prior Empower model

There was improvement in the NIH sentiment overall with the standard appropriations. But just wondering, instrumentation side, how do you expect that to

could you talk about the sequence of an order or a sequence of events that you want to focus on e-commerce service attachment, instrumentation replacement

can you talk – take a minute and talk about how the pharma customers in the U.S. and Europe versus the pharma customers in India are thinking about in this macro environment

Can you elaborate on what's already completed and what remains to be in terms of supply chain realignment in terms of Wilmslow, Singapore versus U.S.

India, Udit, I would love to get your thoughts on 70 bps to 100 bps contribution again strong throughout 2024

first quarter guide, 4% to 7%, a little bit wider than historical pattern. Just want to clarify I know you talked about the full year guide